been infected with HIV resulting in 36 million deaths. UNAIDS estimates that, in 2014 alone, nearly 37 million persons were living with HIV, 2 million were newly infected, and 1.2 million died from their infection, most of whom were in sub-Saharan Africa [3] . HIV, although not as easily transmitted as some viruses, can be transmitted with varying efficiency by multiple modalities: via injection of blood or blood-derived products; from mother-to-child during pregnancy, at delivery or through breast-feeding; and most commonly through sexual intercourse [4] . Fortunately, significant research since the beginning of the epidemic has resulted in the development of more than 40 anti-retroviral drugs that in various combinations can help control the infection [5] . However, despite major gains in the numbers of HIV infected individuals accessing anti-retroviral therapy (ART) in recent years, in 2014 there were still 59% of HIV-positive adults and 68% of children without access to these life-saving medications and importantly, for every person enrolled in treatment, a new infection occurred [6] . This is particularly tragic because effective ART treatment almost eliminates the chance of onward transmission of HIV [7] . Ultimately, even with these significant advances in ART and additional prevention efforts, the development of a safe and effective HIV vaccine remains a global public health priority that is the best hope for preventing, controlling and ending the AIDS pandemic. Even if other treatment and prevention tools are extensively scaled up, modeling analysis shows that a 70-percent-efficacious AIDS vaccine with strong uptake could reduce new annual HIV infections in lower and middle income countries by 44% in 10 years and by 65% in 25 years, ultimately averting tens of millions of infections and saving millions of lives [8] .
Biological feasibility for prophylactic vaccine development
Unlike many infectious diseases, HIV infection does not resolve and give rise to protective immunity against subsequent exposure. While some individuals remain uninfected despite multiple exposures to HIV-1, immune-mediated correlates of protection have not been conclusively identified. Adaptive immune responses against HIV are often directed toward the envelope (Env) protein on the surface of the virus and the capsid protein (Gag) that surrounds and protects the HIV RNA. In people who control virus replication and remain well for many years, Gag-specific CD8+ T cells can inhibit HIV-1 replication in ex vivo-infected cells, a phenotype not observed in those who become ill more quickly [9] . The contribution of cellular immunity to controlling infection has also been observed in simian immunodeficiency virus (SIV) challenge studies of rhesus macaques, although the correlates of protection are not well understood. Pre-clinical studies have shown that recombinant cytomegalovirus (CMV) vectored SIV vaccines induce CD8+ effector memory cells-some conventionally restricted by MHC class I and some unconventional cells-that control SIV to undetectable levels in approximately 50% of immunized macaques [10] . These studies are providing clues toward understanding how best to elicit cellular immune responses that will control and possibly abort HIV infection.
Despite the importance of eliciting a robust cellular immune response, most effective vaccines prevent infection by stimulating the development of neutralizing antibodies. About 5% of HIV infected individuals develop potent neutralizing antibodies against Env that effectively neutralize a broad range of HIV-1 isolates in vitro [11] . A number of broadly neutralizing human monoclonal antibodies (bNAbs) have been isolated and characterized in detail.
In vitro experiments have shown that combinations of such bNAbs can prevent infection of human CD4+ T cells by virtually all HIV isolates. In animal models, passive transfer of several different bNAbs can prevent infection at antibody concentrations that should be achievable by vaccination [12] . The activity and specificity of bNAbs is currently guiding the design of immunogens to elicit broad virus neutralization.
Biological feasibility for therapeutic vaccine development
Therapeutic vaccines for HIV have been evaluated in the past with very limited and inconsistent success, when the model was vaccination during untreated HIV infection [13] . Recently, an alternative approach has been tested, which is to vaccinate patients on highly effective ART, in the hope of preventing virus escape once treatment is stopped or effecting a cure by removing virus reservoirs [14, 15] . This approach will be hindered by the enormous variation of HIV within each infected person, but might hold promise if vaccines that induce sufficiently broad, potent and durable immune responses were employed.
General approaches to vaccine development for this disease for low and middle income country markets
Some two hundred HIV vaccine candidates/regimens have been clinically tested since 1986, yet efficacy trials were completed for only four vaccines [16] , only one of which demonstrated modest efficacy in preventing HIV acquisition [17] . An Env subunit vaccine (gp120, VaxGen) formulated in an alum adjuvant failed to elicit antibodies that could neutralize most tested isolates or to prevent or control HIV infection. An adenovirus type 5 vector with a gag-pol-nef insert (Merck) not only failed to control HIV infection but transiently potentiated HIV acquisition for reasons that remain unclear. One possibility is that repeated vaccination with the Ad5 vector stimulated a generalized immune activation that then provided activated CD4+ target cells for HIV. More recently, a DNA prime boosted with an Ad5 vector delivering gag-pol-nef and three env genes (NIAID Vaccine Research Center) had no effect on HIV infection or viral load in those who became infected [18] . The most promising product, a prime-boost regimen of a Canarypox vector delivering gag-pol-env with a gp120 protein boost (ALVAC -Sanofi; gp120-Vaxgen), designed to elicit both cellular and humoral immunity, demonstrated for the first time that a vaccine could prevent HIV acquisition with 31.2% overall efficacy (RV144).
Once a safe and effective HIV vaccine is developed and licensed, decisions will have to be made regarding which populations to target for vaccination. There is general consensus that priority should be given to high risk groups exposed to HIV through sexual contact or injection drug use. Vaccination of infants has also been proposed and tested in previous early phase clinical studies, however ancillary treatment with drugs or passive antibodies would likely be needed to prevent infection initially, until the child's immune system responds to the vaccination [19, 20] .
Technical and regulatory assessment
HIV vaccine candidates are advanced on the basis of safety and immunogenicity data from animal models and from Phase I clinical trials. The primary HIV animal challenge models include Rhesus macaques challenged with either SIV or a chimeric construct of SIV and HIV Env (SHIV). The SIV or SHIV models are most often chosen based on the availability of appropriate reagents (HIV vaccine candidates made in an SIV version or a SHIV constructed to match the Env in the HIV vaccine candidate). The most common SIV strain used, mac239, is very difficult to neutralize and CD8+ T cells provide limited protection against this virus. SHIV constructs, however, are generally less virulent and are more easily neutralized by antibodies to HIV Env.
More than 250 HIV vaccine Phase I and II clinical trials have been conducted in more than 30 countries [16] . For an updated list of the status of candidates in current developement, please see Table 1 . Although a clear correlate of protection remains elusive, through pre-clinical and clinical evaluation, it is presumed that the best vaccine candidates should elicit neutralizing antibodies, non-neutralizing antibodies that mediate viral clearance through other mechanisms (such as antibody-dependent cell-mediated cytotoxicity-ADCC or virus inhibition, ADCVI), and T cells (primarily CD8+) that suppress virus growth or kill virus-infected cells. For example, efficacy in the RV144 trial was associated with nonneutralizing IgG antibodies to the V1V2 region of Env [21] . To best predict correlates of vaccine efficacy in the absence of additional successful Phase III trials, we must turn to examples of virus control in HIV infected humans and protection from infection or disease in SIV or SHIV models. In humans, CD8+ T cells, particularly those directed at conserved regions of Gag, are correlated with control of virus replication [9, 22] . The general consensus is that vaccine candidates should induce classical CD8+ T effector or effector memory cells (restricted by Class I MHC). Interestingly, however, some of the macaques that were protected from SIV challenge after vaccination with CMV vectors expressing multiple SIV antigens contained unconventional T effector cells [23] . Whether Adeno/Ad5/Ad48 Env A X VRC-HIVADV014-00-VP; VRC-HIVADV038-00-VP; VRC-HIVADV052-00-VP;
VRC these unconventional responses will also be effective in controlling HIV in humans remains to be seen. Phase III HIV vaccine efficacy trials have enrolled a heterogeneous array of populations, including men who have sex with men, injection drug users, heterosexual men and women at high risk for HIV infection, and members of the general population from across global regions in the Americas, South Africa and Thailand. As other proven non-vaccine prevention methods, such as treatment-as-prevention, voluntary medical male circumcision and pre-exposure prophylaxis with antiretroviral drugs become more widely available, it will be more difficult to find appropriate at-risk individuals for vaccine trials, and questions may be raised about the standard of preventive interventions that is required in these trials. Consultation with involved communities will be essential, as emphasized in UNAIDS Good Participatory Practices Guidelines (http://www.unaids.org/sites/default/files/media asset/JC1853 GPP Guidelines 2011 en 0.pdf).
Status
As an outcome of the RV-144 efficacy trial, the Pox-Protein Public Private Partnership, consisting of Sanofi, Novartis, NIAID, Bill & Melinda Gates Foundation, the Military HIV Research Program (MHRP) and the HIV Vaccine Clinical Trials Network, is planning a next phase of efficacy trials that may test the RV144 vaccine regimen in a population of men who have sex with men in Thailand and in heterosexual populations in sub-Saharan Africa [24] . These trials may add additional booster immunizations and more potent adjuvants aimed at extending the durability of protection. If vaccine efficacy of >50% is demonstrated, a licensure application in South Africa is possible as early as 2021. In addition, test of concept efficacy trials are now under consideration for prime-boost regimens utilizing next generation pox vectors (NYVAC; Sanofi), gp120 boosters (Novartis), and DNA (IPPOX Foundation, VICAL) in adaptive clinical trials.
Parallel efforts are developing vaccine candidates addressing the hyper-variability of HIV, aimed at increasing breadth of antibody and T cell responses or focusing responses to conserved regions of the virus. For example, vaccines based on two different hypotheses to elicit broad cellular immune responses are in development. One focuses immune responses to those regions of HIV that are highly conserved and therefore may be required for viral replicative fitness (Oxford University, IAVI, EDCTP) [25] , while the other, termed "mosaic antigens" use in silico methods (Los Alamos National Laboratories) to design immunogens that represent diverse sequences representing the optimal choice of epitopes from all known HIV strains, for broad coverage of circulating viruses (Johnson and Johnson/Janssen, Beth Israel Deaconess Medical Center, NIAID, Ragon Institute) [26] .
Recent technological advances in B cell immunology, next generation sequencing, bioinformatics and structural biology have facilitated the generation of many potent bNAbs. Studies have identified bNAb binding sites on HIV Env, solved structural characterization of Env trimer and Env epitopes with atomic-level precision, and provided a better understanding of the ontogeny of bNAbs in HIV infected individuals [27] . Designing immunogens to elicit these bNAbs remains a major challenge, however, though structural design is now beginning to yield more stable and potent immunogens [28] . bNAbs are also being evaluated for passive prophylaxis and treatment, in phase I-II clinical trials (NIH Vaccine Research Center, Rockefeller University, MHRP) [29] , and for delivery by gene transfer using adeno-associated virus vectors (Children's Hospital of Philadelphia, IAVI) in a phase I trial [30] . Finally, since the RV-144 trial showed that HIV acquisition could be prevented without bNAbs or robust CD8+ cellular immune responses, studies are ongoing to develop vaccines that elicit antibodies that work through other effector mechanisms, such as Fc-mediated interactions with the innate immune system [31] .
Since the HIV vaccine field likely will not see data emerging from the next set of efficacy trials until 2019-2020, current strategies are focused on advancing leading candidates through clinical development, improving vaccine delivery methods and optimizing the next generation of candidates entering clinical development. These include:
• HIV Env Trimers: Recent resolution of the structure of a stabilized HIV Env trimer will lead to clinical evaluation of immunogens more closely mimicking the native Env glycoprotein.
• HIV Antibody Epitope Based Vaccines: Recent elucidation of at least five major epitopes on HIV Env that bind bNAbs will lead to the generation of clinical candidates targeting each of these epitopes, including glycopeptides (see also below), computationally derived scaffolds and novel immunogens designed to bind to putative germline ancestors of the bNAbs. 
Financing the development of an HIV vaccine
HIV vaccine R&D is funded by the public and private sector [32] . In 2014, 841 million USD was available, invested in basic research (29%), preclinical research (33%), clinical research (34%), and other (4%). Funding over the last several years has flat-lined, and is increasingly vulnerable due to its dependency on just two major sources: 84% of funding comes from the US government and the Bill and Melinda Gates Foundation. Over the next 5-10 years, it will be essential for funding to respond to the global pipeline, notably the planned efficacy studies and efforts to leverage new knowledge, such as in the bNAb domain, to design and evaluate novel vaccine approaches.
For HIV vaccines that ultimately reach the state of licensure, initiatives such as The Vaccine Alliance GAVI can help to ensure broad roll-out and access in countries and populations most affected by HIV/AIDS. HIV vaccines, notably those with a high level of efficacy and broad coverage (across HIV variants) will likely be very costefficient, especially when considered against the cost of life-long antiretroviral treatment. Modeling studies indicate that a preventive HIV vaccine could dramatically reduce the number of new infections even if coverage is less than 50% in low-and middleincome countries [33] . A preventive vaccine could be especially beneficial for people who are unable to access or consistency use current methods for preventing HIV infection, due to barriers or dependency on compliance or behavioral change. The best hope for ending the AIDS pandemic is to develop an effective, accessible vaccine that is delivered in the context of a comprehensive prevention strategy.
